No abstract

No abstract

Purpose: Somebody's organ dysfunctions such as heart, lung, kidney, and liver dysfunction are associated with the cardiopulmonary bypass in open-heart surgery.This study aimed effect of the N-acetyl cysteine injection on liver function after on-pump Coronary Artery Bypass Graft SurgeryMethod: In this clinical trial conducted in Golestan Hospital, Ahvaz, Iran, 60 candidates for coronary artery bypass graft surgery were selected based on the inclusion criteria. The candidates were then randomly divided into two intervention and control groups (30 people each).Intervention: Patients received 3 (2 intraoperative and 1 postoperative) doses of IV N-acetyl cysteine (100 mg/kg) (n=30) or placebo (n=30) over 24 hour. The main outcomes were serum Alkaline Phosphatase, Aspartate Aminotransferase, Alanine Aminotransferase, Bilirubin, PTT, and INR at 4 and 48 hours after surgery. Statistical analysis: The dates were analyzed using SPSS 22. Descriptive statistics were reported as mean ± standard deviation for continuous variables and as frequency and percentage for categorical variables. An unpaired t-test was used to compare the parameters with a normal distribution. Statistical significance level was defined at p-value < 0.05.Results: there were significant differences in terms of, ALT, AST, ALP and Bilirubin levels 4(p-value < 0.001) and 48h after surgery (p-value = 0.002).Conclusion: Based on the findings, intravenous administration of N-acetyl cysteine in patients with CABG significantly may be preserved liver function. Trial registry: Registered under No. Trial registration number IRCT20190506043492N2, date of registration :2020.05.23 .Retrospectively registered